Want to join the conversation?
$XRAY's cash flow from operating activities during the three months ended March 31, 2016 was $0.7MM compared to $65.6MM during the three months ended March 31, 2015. The YoverY decrease was primarily related to a $56.9MM larger increase in accounts receivables and payment of approx. $40MM of merger-related expenses.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.